NARA Discovery
NARA Subscribed Scholarly Literature Discovery
Boolean search: climate AND coral · microplastic OR nanoplastic · plastic NOT freshwater · "marine heatwave"
Advanced Search
Topic searches article titles and abstracts. Starts a new search; publisher and year refine it.
Searches article titles and abstracts.
Accepts bare DOI, doi: prefix, or a doi.org URL.
Complete publisher name. Publisher imprints are grouped under their main publisher where applicable.
Exact match by full journal title or ISSN.
–
Refine Results Clear Filters
Collection
NARA Subscribed2
Publisher
Elsevier1
Springer Nature1
Journal
Inflammation Research1
South African Journal of Botany1
Publication Year
20251
20211
Maria A. Protsenko results 2 · Newest (Page 1/1, per page 25)
Export CSV Export RIS Export current results · up to 5,000 records
Author: Maria A. Protsenko ×Clear All Filters
Search Results
Rosa roots and rhizomes as a sustainable source of bioactive compounds with anti-influenza propertiesNARA Subscribed
South African Journal of Botany · 2025 · Vol. 186 · Elsevier
Eugenia A. Karpova; Elena P. Khramova; Margarita V. Kozlova; Lyubov V. Buglova; Olga Yu. Vasil'eva; Tatiana M. Shaldaeva; Larisa N. Shishkina; Ekaterina I. Filippova; Elena V. Makarevich; Maria A. Protsenko; Alexander A. Krasnikov
View Details View Full Text
The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical studyNARA Subscribed
Inflammation Research · 2021 · Vol. 70 · Issue 10-12 · Springer
Nikita V. Lomakin; Bulat A. Bakirov; Denis N. Protsenko; Vadim I. Mazurov; Gaziyavdibir H. Musaev; Olga M. Moiseeva; Elena S. Pasechnik; Vladimir V. Popov; Elena A. Smolyarchuk; Ivan G. Gordeev; Mikhail Yu Gilyarov; Darya S. Fomina; Anton I. Seleznev; Yulia N. Linkova; Ekaterina A. Dokukina; Anna V. Eremeeva; Polina S. Pukhtinskaia; Maria A. Morozova; Arina V. Zinkina-Orikhan; Anton A. Lutckii
Objective and design The aim of this double-blind, placebo-controlled, phase III CORONA clinical trial was to evaluate the efficacy and safety of IL-6 receptor inhibitor levilimab (LVL) in subjects with severe COVID-19. Subjects The study included 217 patients. The eligible were men and non-pregnant women aged 18 years or older, hospitalized for severe COVID-19 pneumonia. Treatment 206 subjects were randomized (1:1) to receive...
View Details View Full Text